Millions of Americans take Ozempic or other glucagon-like peptide-1 (GLP-1) agonist drugs such as Wegovy, Rybelsus, or Mounjaro to manage type-2 diabetes and for weight loss.

While these drugs have helped many people control blood sugar and reduce body weight, emerging scientific evidence suggests a possible link between GLP-1 drugs and a serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). 

In this article, we explain what NAION is, summarize what current research shows about GLP-1 drugs and NAION, and outline what patients need to know about potential vision risks. 

If you or a loved one used Ozempic or other weight loss-diabetes drugs and developed vision loss, blindness, or other eye problems, you may also be entitled to compensation. Contact the lawyers at Hissey Mulderig & Friend by calling toll-free at 1-866-806-8117 or contacting us online to learn more. 

What Is NAION?

NAION stands for non-arteritic anterior ischemic optic neuropathy. This medical condition is also sometimes referred to as an “eye stroke”. 

NAION occurs when blood flow to the front portion of the optic nerve suddenly decreases. The optic nerve carries visual information from the eye to the brain. Without adequate blood flow, cells in the optic nerve can become damaged, leading to vision loss that is often sudden and irreversible. 

NAION typically affects one eye at a time and can cause: 

• Sudden painless loss of vision 
• Blurred or dimmed vision 
• A blind spot in the visual field 
• Reduced color perception 

NAION is considered one of the leading causes of optic nerve-related blindness after glaucoma. Unlike other eye diseases, there is no proven treatment that reliably restores vision once damage has occurred. 

Which GLP-1 Drugs Are Under Investigation?

GLP-1 receptor agonists are a class of medications that mimic the action of the natural hormone glucagon-like peptide-1 to improve insulin secretion, slow gastric emptying, and help control blood sugar. They are widely used in the treatment of Type 2 diabetes and in weight management. 

Common GLP-1 drugs include: 

• Ozempic (semaglutide) 
• Wegovy (semaglutide) 
• Rybelsus (oral semaglutide) 
• Mounjaro (tirzepatide) 
• Saxenda (liraglutide) 

Lawsuits against Ozempic or other GLP-1 drugs have alleged that these medications may increase a patient’s risk of developing NAION.

What Does Current Research Say About NAION and GLP-1 Drugs?

Several observational studies and analyses have examined the potential link between GLP-1 receptor agonists and NAION: 

A Large Ophthalmology Study Found Increased NAION Risk 

A matched cohort study published in JAMA Ophthalmology found a higher risk of NAION in patients prescribed semaglutide compared to patients prescribed non-GLP-1 antidiabetic medications. The study reviewed records from thousands of patients and reported more NAION events among those taking semaglutide. 

Some Analyses Suggest GLP-1 Drugs May Increase Susceptibility 

Clinical resources report that GLP-1 receptor agonists may increase susceptibility to NAION. Some researchers note that GLP-1 receptors are present in the human optic nerve, and changes in blood flow or sympathetic activity could contribute to optic nerve ischemia in rare cases. 

Regulatory Authorities Recognize a Very Rare Risk 

The European Medicines Agency (EMA) reviewed available data and concluded that NAION is a very rare side effect of semaglutide medicines, potentially affecting up to 1 in 10,000 users. The EMA recommended updating product information to include NAION as a side effect and advised patients to seek immediate medical care if they experience sudden vision loss.  

In addition, regulators have recommended that treatment with Ozempic or other drugs containing semaglutide should be stopped if NAION is diagnosed. 

How Common Is NAION With Ozempic and Other GLP-1 Drugs?

According to regulatory analysis: 

• NAION is considered very rare with semaglutide medications. 
• Estimated frequency may be up to 1 in 10,000 people treated, according to the European Medicines Agency. 

Although the condition is rare, its consequences can be severe. Loss of vision due to NAION is often permanent, and early detection plays a key role in patient outcomes. 

Who May Be at Higher Risk?

NAION can occur in individuals for reasons unrelated to medication. Established risk factors include: 

• Diabetes 
• High blood pressure 
• Sleep apnea 
• Cardiovascular disease 
• Age over 50 

These conditions may overlap with the populations most likely to be prescribed GLP-1 receptor agonists. Some researchers believe that pre-existing vascular or optic nerve health issues may increase susceptibility to NAION when taking GLP-1 drugs. 

What Symptoms Should Patients Watch For?

Patients taking Ozempic, Wegovy, Rybelsus, Mounjaro, or similar drugs should be alert for visual symptoms, including: 

• Sudden loss of vision in one eye 
• Blurred or dimmed vision 
• New blind spots 
• Sudden changes in color perception 

If any of these symptoms occur, patients should seek immediate medical evaluation from an eye care professional. 

Why Awareness Matters

GLP-1 medications provide important benefits for diabetes and obesity management. However, emerging research and safety reviews highlight that serious eye conditions like NAION may occur in rare cases. 

Patients and healthcare providers should balance the known benefits of these drugs against the very rare potential for serious vision issues. Regular eye exams and prompt response to visual symptoms can be critical steps in protecting long-term eye health. 

What Should You Do If You Developed NAION After Taking a GLP-1 Drug?

If you or a loved one experienced sudden vision loss or a diagnosis of NAION after taking GLP-1 medications such as Ozempic, Wegovy, Rybelsus, or others: 

1. Obtain complete medical and prescription records. 
2. Ask your treating physician for a detailed eye examination and report. 
3. Discuss the timing of symptom onset relative to medication use. 
4. Ask about alternative treatments and risk mitigation. 

These steps help ensure you understand your medical history and available options. 

Speak With an Ozempic Vision Loss Lawyer

If you used Ozempic, Wegovy, Rybelsus, Mounjaro, Saxenda, or another GLP-1 receptor agonist and were later diagnosed with NAION, sudden vision loss, partial blindness, or permanent blindness, you may be eligible to file a lawsuit and seek financial compensation. 

Drug manufacturers have a legal duty to warn patients and physicians about serious risks associated with their medications. If adequate warnings were not provided, injured patients may have the right to pursue a claim. 

To find out whether you qualify, contact the law firm of Hissey Mulderig & Friend for a free and confidential case evaluation. There are no legal fees or other costs unless our firm wins your case. 

Start the process of filing your claim by calling our office toll free at 1-866-806-8117, or send us a message using the free case evaluation form at the top of this page and speak directly with our GLP-1 vision loss attorneys today.